Payment overview · 2025
General Payments
$1,021.54
37 reported records · 15 companies
Healthcare provider profile · identity verified
Michael H Huber, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LUFKIN, TX · NPI 1235204918
Verified facts
What the public records show
CMS Open Payments records show Michael H Huber, MD received $1,021.54 in general payments during 2025 across 37 reported records.
Penumbra, Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $169.06 | 16.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $162.75 | 15.9% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $160.80 | 15.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.04 | 9.8% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $86.85 | 8.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.81 | 7.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.78 | 6.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.58 | 3.4% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.70 | 3.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.22 | 3.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $26.61 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.26 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.91 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.30 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.87 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,021.54 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $169.06 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $160.80 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $138.65 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $86.85 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $79.22 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.81 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.09 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $48.45 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.75 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.70 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.03 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 180 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1099 | 263 |
| Pantoprazole Sodium | Pantoprazole Sodium | 542 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 519 | 145 |
| Furosemide | Furosemide | 504 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 489 | 130 |
| Alprazolam | Alprazolam | 487 | 80 |
| Lisinopril | Lisinopril | 436 | 116 |
| Gabapentin | Gabapentin | 417 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 416 | 120 |
| Citalopram Hbr | Citalopram Hydrobromide | 360 | 80 |
| Eliquis | Apixaban | 359 | 48 |
| Losartan Potassium | Losartan Potassium | 358 | 99 |
| Meloxicam | Meloxicam | 334 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 303 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 299 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 72 |
| Glimepiride | Glimepiride | 289 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 69 |
| Allopurinol | Allopurinol | 284 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 280 | 42 |
| Omeprazole | Omeprazole | 275 | 76 |
| Simvastatin | Simvastatin | 275 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 33 |
| Montelukast Sodium | Montelukast Sodium | 228 | 62 |
| Potassium Chloride | Potassium Chloride | 213 | 56 |
| Trazodone Hcl | Trazodone Hcl | 207 | 43 |
| Prednisone | Prednisone | 202 | 119 |
| Carvedilol | Carvedilol | 192 | 58 |
| Metformin Hcl | Metformin Hcl | 183 | 58 |
| Ozempic | Semaglutide | 180 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 176 | 40 |
| Tramadol Hcl | Tramadol Hcl | 158 | 35 |
| Finasteride | Finasteride | 154 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 137 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 43 |
| Januvia | Sitagliptin Phosphate | 122 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 118 | 89 |
| Celecoxib | Celecoxib | 118 | 31 |
| Spironolactone | Spironolactone | 115 | 27 |
| Donepezil Hcl | Donepezil Hcl | 111 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 38 |
| Myrbetriq | Mirabegron | 106 | 18 |
| Clonazepam | Clonazepam | 100 | 11 |
| Sertraline Hcl | Sertraline Hcl | 99 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 53 |
| Memantine Hcl | Memantine Hcl | 93 | 15 |
| Pregabalin | Pregabalin | 92 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 14 |
| Alendronate Sodium | Alendronate Sodium | 87 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 13 |
| Synthroid | Levothyroxine Sodium | 82 | 21 |
| Baclofen | Baclofen | 81 | 31 |
| Ezetimibe | Ezetimibe | 80 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 15 |
| Atenolol | Atenolol | 65 | 14 |
| Estradiol | Estradiol | 65 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Ramipril | Ramipril | 63 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 18 |
| Levofloxacin | Levofloxacin | 59 | 43 |
| Trulicity | Dulaglutide | 58 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 22 |
| Farxiga | Dapagliflozin Propanediol | 54 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 16 |
| Fluconazole | Fluconazole | 51 | 25 |
| Famotidine | Famotidine | 50 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 41 |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Glipizide | Glipizide | 44 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 12 |
| Clonidine | Clonidine | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 13 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 39 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 13 |
| Fentanyl | Fentanyl | 32 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Gemtesa | Vibegron | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 11 |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 23 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Armour Thyroid | Thyroid,pork | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Nystatin | Nystatin | 22 | 11 |
| Temazepam | Temazepam | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 19 |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Modafinil | Modafinil | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 16 |
| Digoxin | Digoxin | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Thyroid | Thyroid,pork | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Meropenem | Meropenem | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Nystop | Nystatin | 16 | 11 |
| Roflumilast | Roflumilast | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,021.54 · 37 records | Penumbra, Inc. | Auvelity, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GEMTESA, Indigo System, JARDIANCE, LEQVIO, MYFEMBREE, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Wegovy, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error